BeBetter Med (SHSE:688759) Research & Development: ¥135.41 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688759 BeBetter Med Inc SHSE:688759
4 GF Score
Price ¥23.20
View Full Analysis

What is BeBetter Med Research & Development?

BeBetter Med SHSE:688759 -17.26% 4 Research & Development is ¥135.41 Mil as of Mar. 2026. GuruFocus rates SHSE:688759 with a GF Score™ of 4/100.

Research & Development is the aggregate amount of research and development expenses during the year. BeBetter Med's Research & Development for the three months ended in Mar. 2026 was ¥40.73 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ¥135.41 Mil.

BeBetter Med  (SHSE:688759) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

BeBetter Med Research & Development Related Terms

BeBetter Med Research & Development Historical Data

* Premium members only.

The historical data trend for BeBetter Med's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BeBetter Med Research & Development Chart

BeBetter Med Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 115.99 166.74 157.65 120.29 120.96

BeBetter Med Quarterly Data
Dec19 Dec20 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Dec23 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.28 27.81 27.47 39.41 40.73
SHSE:688759
4GF Score
BeBetter Med Inc SHSE:688759
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BeBetter Med Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥135.41 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ¥135.41 Mil mean?
BeBetter Med (SHSE:688759) has a Research & Development of ¥135.41 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on BeBetter Med and its competitors.
Is BeBetter Med's Research & Development too high?
BeBetter Med's current Research & Development is ¥135.41 Mil. Overall, BeBetter Med has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does BeBetter Med's Research & Development compare to VRTX and REGN?
BeBetter Med's Research & Development of ¥135.41 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on BeBetter Med and its competitors. BeBetter Med's current Research & Development is ¥135.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeBetter Med stock overvalued right now?
BeBetter Med (SHSE:688759) has a current Research & Development of ¥135.41 Mil. The current Research & Development is ¥135.41 Mil. BeBetter Med's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For BeBetter Med (SHSE:688759), the current Research & Development is ¥135.41 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BeBetter Med Business Description

Address No. 25 Yayingshi Road, Room 802, 8th Floor, Building A-3, Science City, High-tech Industrial Development Zone, Guangzhou, Guangdong, CHN, 510663
BeBetter Med Inc is a biopharmaceutical company based in China, focusing on independent research and development of drugs. The company focuses on developing novel medicines for treating cancers, autoimmune diseases, and other severe conditions. Key products include the PI3K/HDAC dual inhibitor BEBT-908 and multiple drugs in clinical trial phases targeting cancers. It's a United States subsidiary BeBetter Pharma specializes in next-generation siRNA therapeutics using proprietary delivery platforms aimed at complex diseases like kidney disorders, metabolic and liver diseases, and neurodegenerative conditions. Its pipeline includes oral and injectable drug candidates, some in late-stage trials, and aims to address unmet medical needs through novel mechanisms.
4GF Score

Get the complete analysis for SHSE:688759

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥23.20
Price